Will any FDA-approved GLP-1 agonists be withdrawn from the market for safety reasons by 01/01/2025?
➕
Plus
14
Ṁ946
Jan 1
12%
chance

GLP-1 agonists, such as semaglutide (ozempic/wegovy), tirzepatide (mounjaro), and dulaglutide (Trulicity), are becoming popular for weight loss and Type-2 diabetes treatment. This market resolves positively if any approved GLP-1 agonists for either T2D or weight loss are withdrawn from the market due to safety reasons by the listed date. This applies either if the FDA mandates it or if the company withdraws the drug voluntarily.

Get
Ṁ1,000
and
S3.00
Sort by:
predicts NO

made a market that breaks this out by end year and added a M5k subsidy: https://manifold.markets/AndyMartin/m5k-subsidy-will-any-fdaapproved-gl

© Manifold Markets, Inc.Terms + Mana-only TermsPrivacyRules